Developing a vaccine to fight KSHV infection in nonhuman primates
Official title: Targeting CD180 to induce anti-KSHV response in nonhuman primates
Funded at Oregon Health & Science University · NIH-11003457 · Data updated 2026-11-12
This study is testing two different vaccine methods to see which one helps the immune system fight off the virus that causes Kaposi's Sarcoma, using nonhuman primates to find the best option for future vaccines.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Oregon Health & Science University NIH-funded |
| Lab location | 1 site (Portland, United States) |
| Project start | August 1, 2024 |
| Project end | July 31, 2029 |
| Funding year | 2024 |
| Award (this year) | $1,212,634 |
| NIH project number | 1U01CA295049-01 |
| Project ID | NIH-11003457 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research would be individuals at high risk for KSHV infection or those with compromised immune systems.
✕Less likely to help
Patients who are not at risk for KSHV infection or those who do not have immune system challenges may not benefit from this research.
What this research studies
This research aims to explore two potential targets for a vaccine against Kaposi's Sarcoma-associated Herpesvirus (KSHV) in nonhuman primates. It will evaluate the effectiveness of two different vaccine strategies: one using mRNA-lipid nanoparticles, which have shown success in other vaccines, and another that targets CD180, a receptor that can enhance immune responses. By using a model that mimics KSHV infection, the researchers hope to determine which approach generates a stronger immune response and offers better protection against the virus.
Why it matters
Potential benefit: If successful, this research could lead to a new vaccine that effectively protects against KSHV, potentially reducing the incidence of related cancers in humans.
How similar studies have gone: Previous research has shown promise in using mRNA vaccines and targeting immune receptors like CD180, indicating potential for success in this novel approach.
Where this research is happening
-
Oregon Health & Science University
Portland, United States Active
Researchers
- Principal investigator: Wong, Scott W — Oregon Health & Science University
- Study coordinator: Wong, Scott W
Related research
Other NIH-funded projects on the same topics.
-
Understanding how a protein affects nerve cell movement in Alzheimer's disease
This study is looking at how a protein called APP affects the growth and movement of nerve cells, which is important for understanding Alzheimer's disease, and it aims to find out how problems with this protein might lead to nerve cell damage.
-
Understanding how the bone marrow environment drives AML resistance
A large NIH-funded project at Oregon Health & Science University is studying how the body’s own cell surroundings help acute myeloid leukemia become resistant to treatment, with potential paths to better therapies for patients.
-
Improving Safety at Work with a Low-Resource mHealth Program in Malaysia (and beyond)
A low-cost mobile health program to improve safety culture in Malaysian workplaces, with plans to adapt the approach for U.S. workers in high-risk industries.
-
Oregon Healthy Workplace Initiative for Better Health
A multi-site effort aims to improve the health and safety of workers by coordinating research, tools, and interventions across workplaces.
-
Understanding how AML cells become resistant to therapy over time
This project looks at why acute myeloid leukemia stops responding to treatment and how to design better drug combinations to prevent relapse.
-
Mechanisms and Countermeasures for Ultra-Potent Synthetic Opioid Overdose
A small, focused NIH grant aims to understand why ultra-potent synthetic opioids cause severe overdose and to explore potential countermeasures to keep people safe.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.